MedTrace Logo

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-08-26

No results posted yet for this study

Summary

This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.

Conditions

Interventions

DRUG

CXA-10

(10-nitro-9(E)-octadec-9enoic acid)

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Innovative Analytics

    collaborator UNKNOWN

  • Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

    collaborator OTHER

  • Complexa, Inc.

    lead INDUSTRY

Principal Investigators

  • Theo Danoff, MD · Complexa, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-09
Primary Completion
2020-08-12
Completion
2020-08-12
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04053543 on ClinicalTrials.gov